Peptide Chemical Compatibility and Stability in the Lab

Peptides are not inert powders. In solution they can oxidize, deamidate, aggregate, and bind metals, and each of those changes produces a different chemical species. This post summarizes what the pharmaceutical and analytical literature says about these pathways in vitro, and why samples containing several peptides are harder to characterize than single-peptide samples.

This post is limited to chemical stability and analytical characterization. It does not cover preparation for any use.

Chemical vs physical instability

The protein and peptide stability literature separates two kinds of change:

Chemical instability. Covalent changes such as oxidation, deamidation, and bond cleavage.
Physical instability. Non-covalent changes such as aggregation, adsorption to surfaces, and loss of structure.

The two are linked. A 2010 update of the widely cited 1989 Pharmaceutical Research review has a section on how chemical and physical instability affect each other (PMID: 20143256). A covalent change can shift a peptide's charge or shape, and that can change how it self-associates.

Oxidation: Met, Cys, Trp (and His, Tyr)

Methionine, cysteine, histidine, tryptophan, and tyrosine are the residues most susceptible to oxidation because they react readily with reactive oxygen species (PMID: 18623513). Oxidation can come from:

Contaminating oxidants
Transition metal ions, acting as catalysts
Light

The extent is also influenced by pH, temperature, and buffer composition (PMID: 18623513).

Mechanism matters. Li, Schöneich, and Borchardt distinguish two mechanisms (PMID: 18623513):

Non-site-specific oxidation, driven by oxidants in the system. Antioxidants or radical scavengers can inhibit it.
Metal-catalyzed oxidation, which is site-specific. Adding antioxidants can actually speed up this kind of oxidation. Chelating agents are the studied alternative.

What gets modified. Stadtman's review of metal-catalyzed oxidation reports that Fe or Cu, oxygen, and an electron donor produce reactive species at metal-binding sites. Only one or a few residues near the metal are usually modified (PMID: 2283087). Reported products include (PMID: 2283087):

Methionine converted to methionine sulfoxide
Cysteine converted to mixed disulfides
Histidine converted to asparagine or aspartate
Proline and arginine converted to carbonyl derivatives

Different oxidants hit different residues. A Genentech study used parathyroid hormone (1–34) as a model and measured oxidation by LC, peptide mapping, and mass spectrometry (PMID: 19455640):

Hydrogen peroxide mainly oxidized the methionines.
A free-radical generator (AAPH) and peroxide plus iron oxidized both methionine and tryptophan.
Histidine oxidation appeared when copper was used instead of iron.

Oxidized forms are distinct molecules. Thymosin beta-4 has a methionine at position 6, visible in its N-terminal sequence Ac-SDKPDMAEIEKFDKS (PMID: 30063851). Its sulfoxide form has been studied as a separate species with its own reported activity (PMID: 23820300). An oxidized peptide is not just a "less pure" version of the parent. It is a different molecule.

Deamidation

Deamidation of asparagine (Asn) and glutamine (Gln) residues changes a peptide's charge and conformation over time (PMID: 11606750).

Kinetics can be fast. In the model hexapeptide Val-Tyr-Pro-Asn-Gly-Ala, deamidation had a half-life of only 1.4 days at 37 °C and pH 7.4 (PMID: 3805008). It proceeded through a succinimide intermediate, which then hydrolyzed and racemized. The products were a mixture of L- and D-aspartyl and isoaspartyl peptides (PMID: 3805008).

Sequence matters. Replacing the glycine after Asn with a bulky leucine or proline slowed degradation 33- to 50-fold (PMID: 3805008).

pH matters. Working with the same model hexapeptide, Patel and Borchardt found that deamidation depended strongly on pH, temperature, and buffer composition (PMID: 2395797):

From pH 5 to 12, it went through the succinimide intermediate and gave both Asp and isoAsp products.
From pH 7 to 11, buffer catalysis was observed.
At acidic pH, the side-chain amide was hydrolyzed directly, giving only the Asp product.

For analysis, this means one Asn residue can produce several species, including isomers of the same mass. Chromatography then has to separate them.

Aggregation, pH, and solution conditions

A 2017 Cambridge review of peptide aggregation lists the factors that influence physical stability (PMID: 29147559):

Intrinsic: sequence, net charge
Solution: concentration, pH, excipients, impurities
Chemical: degradation and modification
Physical: surfaces and interfaces, temperature, pressure, agitation, lyophilization

Aggregates can be amorphous or highly structured fibrils (PMID: 29147559).

pH affects net charge, and net charge affects self-association (PMID: 29147559). Buffer composition affects both oxidation (PMID: 18623513) and deamidation (PMID: 2395797). A 1999 review in the International Journal of Pharmaceutics covers these solution effects for proteins in aqueous systems in detail (PMID: 10460913).

Copper peptide complexes

Copper peptides raise a specific compatibility question: does the copper stay put?

Affinity is high but not absolute. GHK binds Cu(II) with a conditional dissociation constant of about 7.0 × 10⁻¹⁴ M at pH 7.4. The albumin-derived motif DAHK binds slightly more tightly, at about 2.6 × 10⁻¹⁴ M (PMID: 21898044).
The complex is labile. In solution, Cu(II)-GHK leaves one equatorial coordination site open. It forms ternary complexes with glycine or histidine and exchanges copper rapidly between GHK molecules (PMID: 21780203).
Copper moves between peptides. Rate constants for Cu(II) transfer between GHK-type peptides and to DAHK have been measured directly (PMID: 29648796).
Copper can drive oxidation. In the parathyroid hormone model, copper produced histidine oxidation (PMID: 19455640). Metal-catalyzed oxidation concentrates damage at metal-binding sites (PMID: 2283087).

Taken together, these findings mean a Cu(II) peptide complex is dynamic rather than fixed. Copper can exchange between ligands, form ternary complexes, or take part in site-specific oxidation, and each outcome is a species an analytical method may need to resolve.

Even a single synthetic peptide carries a range of possible related impurities. A 2014 review from Ghent University catalogs them (PMID: 25044089):

Synthesis-related: deletion and insertion sequences, diastereomers from racemization, protecting-group adducts, side-chain reaction products, oxidized forms, and dimers or oligomers
Counter-ions: such as trifluoroacetate
Contamination: unrelated peptides, which the authors link to inadequate GMP
Degradation products: β-elimination, diketopiperazine, pyroglutamate, and succinimide

The same review notes that such impurities can distort early functional studies and lead to wrong conclusions (PMID: 25044089). Same-mass isomers, such as isoAsp products (PMID: 3805008), are a particular challenge because mass spectrometry alone may not distinguish them, so chromatographic separation matters.

Research peptides are listed in our catalog at /shop.

References

Beuning CN et al. Inorg Chem. 2018. PMID: 29648796. doi:10.1021/acs.inorgchem.8b00182
D'Hondt M et al. J Pharm Biomed Anal. 2014. PMID: 25044089. doi:10.1016/j.jpba.2014.06.012
Evans MA et al. Nat Commun. 2013. PMID: 23820300. doi:10.1038/ncomms3081
Geiger T, Clarke S. J Biol Chem. 1987. PMID: 3805008
Hureau C et al. Chemistry. 2011. PMID: 21780203. doi:10.1002/chem.201100751
Ji JA et al. J Pharm Sci. 2009. PMID: 19455640. doi:10.1002/jps.21746
Li S, Schöneich C, Borchardt RT. Biotechnol Bioeng. 1995. PMID: 18623513. doi:10.1002/bit.260480511
Manning MC et al. Pharm Res. 2010. PMID: 20143256. doi:10.1007/s11095-009-0045-6
Patel K, Borchardt RT. Pharm Res. 1990. PMID: 2395797. doi:10.1023/a:1015807303766
Robinson NE, Robinson AB. PNAS. 2001. PMID: 11606750. doi:10.1073/pnas.221463198
Shah R et al. Expert Opin Biol Ther. 2018. PMID: 30063851. doi:10.1080/14712598.2018.1478961
Stadtman ER. Free Radic Biol Med. 1990. PMID: 2283087. doi:10.1016/0891-5849(90)90006-5
Trapaidze A et al. J Biol Inorg Chem. 2012. PMID: 21898044. doi:10.1007/s00775-011-0824-5
Wang W. Int J Pharm. 1999. PMID: 10460913. doi:10.1016/s0378-5173(99)00152-0
Zapadka KL et al. Interface Focus. 2017. PMID: 29147559. doi:10.1098/rsfs.2017.0030

This article summarizes published laboratory research for informational purposes. It is not medical advice and does not suggest any use in humans or animals.

Research Use Only. Sold for in vitro laboratory research. Not for human or veterinary use. Not a drug, food, cosmetic, or medical device. These materials have not been evaluated by the FDA. 21+.